Cytotoxicity Profile and Autophagic Activity of Ranibizumab and Aflibercept on Healthy Human Retina Pigment Epithelium Cells: An In Vitro Experimental Study
Keywords:
In vitro, Autophagy, CytotoxicityAbstract
Vascular endothelial growth factor (VEGF) plays a central role in retinal neovascular diseases, and anti-VEGF agents such as ranibizumab and aflibercept are widely used to control these conditions. This study aimed to compare the cytotoxic and autophagic effects of ranibizumab and aflibercept on human retinal pigment epithelium (ARPE-19) cells in vitro. ARPE-19 cells were treated with incremental doses of each drug (1.25× to 40× the clinical concentration). Cell viability was assessed using the MTT assay, and mRNA expressions of autophagy-related genes Beclin1 and ATG4 were quantified by qRT-PCR. Ranibizumab significantly reduced cell viability at 20× and 40× doses compared with the control, whereas aflibercept did not show notable cytotoxicity even at the highest tested concentrations. Both drugs influenced autophagy pathways in different ways: ranibizumab caused less inhibition of Beclin1 expression than aflibercept (p < 0.05), while both agents induced a non-significant increase in ATG4 expression. These results suggest that aflibercept may have a lower cytotoxic potential at supratherapeutic concentrations and that both drugs can modulate autophagic activity in retinal pigment epithelium cells. Understanding these cellular effects may help optimize the safety and long-term application of anti-VEGF therapy in retinal diseases.
References
Adamis AP, Shima DT. 2005. The role of vascular endothelial growth factor in ocular health and disease. Retina, 25(2), 111-118.
Ammar DA, Mandava N, Kahook MY. 2013. The effects of aflibercept on the viability and metabolism of ocular cells in vitro. Retina, 33(5), 1056-1061.
Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Progress in retinal and eye research. 2015 Nov 1;49:67-81.
Du JH, Li X, Li R, Cheng BX, Kuerbanjiang M, Ma L. 2017. Role of autophagy in angiogenesis induced by a high-glucose condition in RF/6A cells. Ophthalmologica, 237(2), 85-95.
Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. 1996. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Experimental eye research, 62(2), 155-170.
Emir SB, Ucgun NI, Fikret CZ. 2022. Cytotoxicity of Anti-VEGF Agents: An Experimental Study on ARPE-19 Cell Culture. Archives of Clinical and Biomedical Research, 6: 800-806.
Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nature medicine, 9(6), 669-676.
Folkman J. 2006. Angiogenesis. Annu. Rev. Med., 57(1), 1-18.
Folkman J. 2007. Angiogenesis: an organizing principle for drug discovery?. Nature reviews Drug discovery, 6(4), 273-286.
Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Kroemer G. 2009. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death & Differentiation, 16(8), 1093-1107.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, McAllister IL. 2019. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA ophthalmology, 137(4), 372-379.
He C, Levine B. 2010. The beclin 1 interactome. Current opinion in cell biology, 22(2), 140-149.
Karagoz IK, Allahverdiyev A, Demircioglu A, Abamor ES, Dinparvar S, Bagirova M. 2021. Producing Aflibercept Loaded Poly (Lactic Co Glycolic Acid)[Plga] Nanoparticles As A New Ocular Drug Delivery System and Its Challenges. Feb Fresenıus Envıronmental Bulletın, 1481.
Kroemer G, Mariño G, Levine B. 2010. Autophagy and the integrated stress response. Molecular cell, 40(2), 280-293.
Liang J, Piao Y, Henry V, Tiao N, de Groot JF. 2015. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget, 6(31), 31479.
Liu J, Fan L, Wang H, Sun G. 2016. Autophagy, a double-edged sword in anti-angiogenesis therapy. Medical oncology, 33(1), 10.
Lytvynchuk L, Sergienko A, Lavrenchuk G, Petrovski G. 2015. Antiproliferative, apoptotic, and autophagic activity of ranibizumab, bevacizumab, pegaptanib, and aflibercept on fibroblasts: implication for choroidal neovascularization. Journal of Ophthalmology, 2015(1), 934963.
Malik D, Tarek M, del Carpio JC, Ramirez C, Boyer D, Kenney MC, Kuppermann BD. 2014. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. British Journal of Ophthalmology, 98(Suppl 1), i11-i16.
Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. 2014. Self-consumption: the interplay of autophagy and apoptosis. Nature reviews Molecular cell biology, 15(2), 81-94.
Maruyama T, Noda NN. 2018. Autophagy-regulating protease Atg4: structure, function, regulation and inhibition. The Journal of antibiotics, 71(1), 72-78.
Miaomiao W, Chunhua L, Xiaochen Z, Xiaoniao C, Hongli L, Zhuo Y. 2016. Autophagy is involved in regulating VEGF during high-glucose-induced podocyte injury. Molecular biosystems, 12(7), 2202-2212.
Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M. 2016. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro. European Journal of Ophthalmology, 26(5), 425-430.
Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. 2003. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. Journal of Biological Chemistry, 278(23), 20915-20924.
Saenz-de-Viteri M, Fernández-Robredo P, Hernández M, Bezunartea J, Reiter N, Recalde S, García-Layana A. 2016. Single-and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions. Biochemical pharmacology, 103, 129-139.
Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Aisenbrey S. 2013. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. British Journal of Ophthalmology, 97(7), 917-923.
Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A. 2018. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium. Experimental eye research, 171, 1-11.
Segatto M, Fico E, Gharbiya M, Rosso P, Carito V, Tirassa P, Lambiase A. 2019. VEGF inhibition alters neurotrophin signalling pathways and induces caspase‐3 activation and autophagy in rabbit retina. Journal of Cellular Physiology, 234(10), 18297-18307.
Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Szurman P. 2007. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 245(12), 1837-1842.
Wang Y, Yao Y, Li R, Wu B, Lu H, Cheng J, Du J. 2021. Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept, Conbercept) on autophagy and its effect on neovascularization in RF/6A cells. Microvascular research, 138, 104207.
Ye F, Kaneko H, Hayashi Y, Takayama K, Hwang SJ, Nishizawa Y, Terasaki H. 2016. Malondialdehyde induces autophagy dysfunction and VEGF secretion in the retinal pigment epithelium in age-related macular degeneration. Free Radical Biology and Medicine, 94, 121-134.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 International Journal of Veterinary and Animal Research (IJVAR)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
